Telmisartan Actavis Европска Унија - Пољски - EMA (European Medicines Agency)

telmisartan actavis

actavis group ptc ehf - telmisartan - nadciśnienie - Środki działające na układ renina-angiotensyna - hypertensiontreatment nadciśnienia tętniczego u dorosłych. choroby układu sercowo-naczyniowego preventionreduction sercowonaczyniową chorobliwość u pacjentów z:manifest aterotrombotičeskih choroby sercowo-naczyniowe (w historii choroby niedokrwiennej serca, udaru mózgu lub choroby naczyń obwodowych) lub cukrzycy typu 2 z udokumentowanymi uszkodzenia narządów docelowych.

Tolucombi Европска Унија - Пољски - EMA (European Medicines Agency)

tolucombi

krka, d.d., novo mesto - telmisartan, hydrochlorothiazide - nadciśnienie - telmisartan i leki moczopędne - połączenie stałe dawki lek tolucombi (80 mg telmisartanu/25 mg hydrochlorotiazydu) jest wskazany u dorosłych, których ciśnienie krwi nie jest odpowiednio kontrolowane na lek tolucombi 80 mg/12. 5 mg (80 mg telmisartanu/12. 5 mg hydrochlorotiazydu) lub dorosłych, którzy uprzednio byli ustabilizowani na telmisartanie i hydrochlorotiazydzie podanymi osobno.

Baqsimi Европска Унија - Пољски - EMA (European Medicines Agency)

baqsimi

eli lilly nederland b.v. - glukagon - cukrzyca - hormony trzustki, hormony glycogenolytic - baqsimi jest wskazany w leczeniu ciężkiej hipoglikemii u dorosłych, młodzieży i dzieci w wieku od 4 lat i starszych z cukrzycą.

Lyumjev (previously Liumjev) Европска Унија - Пољски - EMA (European Medicines Agency)

lyumjev (previously liumjev)

eli lilly nederland b.v. - insulina lispro - cukrzyca - leki stosowane w cukrzycy - leczenie cukrzycy u dorosłych, młodzieży i dzieci w wieku 1 roku i powyżej. leczenie cukrzycy u dorosłych.

Edistride Европска Унија - Пољски - EMA (European Medicines Agency)

edistride

astrazeneca ab - monohydrat propanoilu dapagliflozyny - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - leki stosowane w cukrzycy - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. oprócz innych leków do leczenia cukrzycy typu 2 . for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 i 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Forxiga Европска Унија - Пољски - EMA (European Medicines Agency)

forxiga

astrazeneca ab - monohydrat propanoilu dapagliflozyny - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - leki stosowane w cukrzycy - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. oprócz innych leków do leczenia cukrzycy typu 2 . for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 i 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Invokana Европска Унија - Пољски - EMA (European Medicines Agency)

invokana

janssen-cilag international nv - canagliflozin - diabetes mellitus, type 2 - leki stosowane w cukrzycy - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 i 5.

Xigduo Европска Унија - Пољски - EMA (European Medicines Agency)

xigduo

astrazeneca ab - chlorowodorek metforminy, monohydrat dapagliflozin propanodiol - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - xigduo jest wskazany u dorosłych w leczeniu cukrzycy typu 2, jako uzupełnienie diety i ćwiczeń:• u pacjentów niedostatecznie kontrolowanych o ich maksymalnej tolerowanej dawce tylko metformina • w połączeniu z innymi lekami do leczenia cukrzycy u pacjentów niedostatecznie kontrolowanych metforminą i te leki• u pacjentów już leczonych kombinacją dapagliflozin i metformina w postaci oddzielnych tabletek. na podstawie wyników badań w odniesieniu do terapii skojarzonej, wpływ na kontrolę glikemii i zdarzeń sercowo-naczyniowych, a w badanych populacjach, patrz rozdziały 4. 4, 4. 5 i 5.

Onglyza Европска Унија - Пољски - EMA (European Medicines Agency)

onglyza

astrazeneca ab - Саксаглиптин - diabetes mellitus, type 2 - leki stosowane w cukrzycy - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.